MARKET

SVRA

SVRA

Savara Inc
NASDAQ
6.42
+0.05
+0.78%
Opening 11:51 12/05 EST
OPEN
6.44
PREV CLOSE
6.37
HIGH
6.58
LOW
6.31
VOLUME
2.02M
TURNOVER
--
52 WEEK HIGH
6.61
52 WEEK LOW
1.890
MARKET CAP
1.31B
P/E (TTM)
-12.0000
1D
5D
1M
3M
1Y
5Y
1D
Savara (SVRA): Valuation Check After New European Patent Win and Rising Conference-Driven Investor Interest
Simply Wall St · 2d ago
Savara Inc. ticks higher amid takeover speculation
Seeking Alpha · 2d ago
Savara rumor highlighted in Betaville blog
TipRanks · 2d ago
Savara issues patent for Molbreevi from European Patent Office
TipRanks · 3d ago
Savara, PARI Granted European Patent Titled 'Drug-Device Combination Comprising a Liquid Solution and a Nebulizer for Aerosolization of the Liquid Solution.'
Benzinga · 3d ago
Savara Inc. Unveils New Therapies Targeting Rare Respiratory Diseases
Reuters · 3d ago
Savara Inc. and PARI Granted European Patent Covering MOLBREEVI and eFlow Nebulizer Combination
Reuters · 3d ago
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
Barchart · 3d ago
More
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Webull offers Savara Inc stock information, including NASDAQ: SVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SVRA stock methods without spending real money on the virtual paper trading platform.